Federal Grant Award Summary

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $802,418 to The Global Alliance For TB Drug Development Inc. (TB Alliance) on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award supports the TB LATITUDE (Long-Acting Treatment Innovation for Tuberculosis Drug Effectiveness) project, which aims to develop long-acting injectable (LAI) formulation technologies for tuberculosis treatment. The research focuses on optimizing LAI-based regimens for four drugs from TB Alliance's pipeline—TBAJ-876, TBAJ-587, telacebec, and pretomanid—to reduce active TB treatment duration to two months or less for both drug-sensitive and drug-resistant tuberculosis cases, thereby significantly reducing treatment burden on patients currently requiring up to six months of daily oral therapy.

The project is structured in two phases. The first phase (R61) encompasses formulation developability assessment, stability testing, in vitro release characterization, in vivo pharmacokinetic studies, and pharmacokinetic/pharmacodynamic modeling and correlation analysis using mouse infection studies. Upon completion of the R61 phase, up to four drug and formulation configurations will advance to the second phase (R33), which focuses on nonclinical evaluation and transition toward clinical development. The award period extends through April 30, 2028, with performance conducted in New York, New York.